A Sequential Membrane Process of Ultrafiltration Forward Osmosis and Reverse Osmosis for Poultry Slaughterhouse Wastewater Treatment and Reuse.

To address some challenges of food security and sustainability of the poultry processing industry, a sequential membrane process of ultrafiltration (UF), forward osmosis (FO), and reverse osmosis (RO) is proposed to treat semi-processed poultry slaughterhouse wastewater (PSWW) and water recovery. The pretreatment of PSWW with UF removed 36.7% of chemical oxygen demand (COD), 38.9% of total phosphorous (TP), 24.7% of total solids (TS), 14.5% of total volatile solids (TVS), 27.3% of total fixed solids (TFS), and 12.1% of total nitrogen (TN). Then, the PSWW was treated with FO membrane in FO mode, pressure retarded osmosis (PRO) mode, and L-DOPA coated membrane in the PRO mode. The FO mode was optimal for PSWW treatment by achieving the highest average flux of 10.4 ± 0.2 L/m2-h and the highest pollutant removal efficiency; 100% of COD, 100% of TP, 90.5% of TS, 85.3% of TVS, 92.1% of TFS, and 37.2% of TN. The performance of the FO membrane was entirely restored by flushing the membrane with 0.1% sodium dodecyl sulfate solution. RO significantly removed COD, TS, TVS, TFS, and TP. However, TN was reduced by only 62% because of the high ammonia concentration present in the draw solution. Overall, the sequential membrane process (UF-FO-RO) showed excellent performance by providing high rejection efficiency for pollutant removal and water recovery.

Prevalence of Thyroid Dysfunction in Patients With Hepatitis C.

INTRODUCTION: Hepatitis C has been linked to a multitude of autoimmune disorders, including rheumatoid arthritis, thyroid disease, cryoglobulinemia, immune thrombocytopenic purpura, systemic lupus erythematosus, and Sjögren's syndrome. In this study, efforts were made to draw a parallel between hepatitis C and thyroid dysfunction. METHODS: This case-control study was conducted between June 2020 and March 2021 in the gastroenterology ward of a tertiary care hospital. We enrolled 300 hepatitis C-positive patients in this study through consecutive convenient non-probability sampling. In addition, 300 patients without hepatitis C were signed up as a control group. Blood sampling for thyroid function tests was conducted via phlebotomy from the cubital vein and the samples were dispatched to the laboratory for further study. RESULTS: The control group had more euthyroid patients as compared to patients with hepatitis C (74.6% vs. 89.6%; p-value: <0.01). Hepatitis C patients had more cases of primary hypothyroidism compared to the control group (10.6% vs. 4.6%; p-value: 0.005). Similarly, patients with hepatitis C had a higher prevalence of subclinical hypothyroidism compared to the control group (6.0% vs. 1.3%; p-value: 0.002). CONCLUSION: Hepatitis C patients have a high frequency of thyroid dysfunction, particularly primary hypothyroidism and subclinical hypothyroidism. Therefore, it is important to ensure regular screening for early prognosis and avoid treatment modalities that are known to cause thyroid abnormalities.

Role of Cod Liver Oil in Reducing Elevated Lipid Parameters.

Introduction The health benefits of cod oil, which includes omega-3 fatty acids, have been of considerable interest to medicine due to its promising results. Studies have shown successful therapeutic effects of a high dietary intake of omega-3 fatty acids by reducing the synthesis of very-low-density lipoprotein, with subsequent low levels of serum triglycerides.  Methods This single-blind placebo-controlled two-arm interventional study was conducted in the internal medicine unit of a tertiary care hospital from October 2020 to April 2021. 600 treatment naïve patients with elevated cholesterol levels and/or elevated low-density lipoprotein (LDL) were enrolled in the study and randomized into two groups. The study group received 415 mg cod liver oil daily as a capsule in a bottle, in addition to 10 mg rosuvastatin. On the other hand, the control group received 10 mg rosuvastatin with placebo capsules in an identical bottle. Participants were followed up on day 30. Results There was relatively more significant reductions in the total cholesterol (152.22 ± 29.75 mg/dL vs. 171.65 ± 31.21 mg/dL; p-value: <0.0001) and LDL (72.41 ± 27.52 mg/dL vs. 79.15 ± 29.12 mg/dL; p-value: <0.0001) in the intervention group compared to the placebo group after day 30. There was a significant reduction in all lipid values in both groups at day 30 as compared to day 0. Conclusion Our study indicates that cod liver oil in addition to rosuvastatin reduces cholesterol more compared to rosuvastatin alone. However, in all cases, lifestyle changes should be the first modification adopted by the patients. Further large-scale trials are needed to examine the role of cod liver oil in reducing lipid values.